Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
103.15
+1.07 (1.05%)
At close: Feb 11, 2026, 4:00 PM EST
103.41
+0.26 (0.25%)
After-hours: Feb 11, 2026, 6:25 PM EST
Nuvalent Employees
Nuvalent had 218 employees as of September 30, 2025. The number of employees increased by 91 or 71.65% compared to the same quarter last year.
Employees
218
Change
91
Growth
71.65%
Revenue / Employee
n/a
Profits / Employee
-$1,749,702
Market Cap
8.01B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 218 | 91 | 71.65% |
| Jun 30, 2025 | 200 | 85 | 73.91% |
| Mar 31, 2025 | 162 | 56 | 52.83% |
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Sep 30, 2024 | 127 | 38 | 42.70% |
| Jun 30, 2024 | 115 | 37 | 47.44% |
| Mar 31, 2024 | 106 | 36 | 51.43% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Sep 30, 2023 | 89 | 32 | 56.14% |
| Jun 30, 2023 | 78 | 26 | 50.00% |
| Mar 31, 2023 | 70 | 22 | 45.83% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Sep 30, 2022 | 57 | 21 | 58.33% |
| Jun 30, 2022 | 52 | 25 | 92.59% |
| Mar 31, 2022 | 48 | 31 | 182.35% |
| Dec 31, 2021 | 40 | 23 | 135.29% |
| Sep 30, 2021 | 36 | - | - |
| Jun 30, 2021 | 27 | - | - |
| Mar 31, 2021 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jazz Pharmaceuticals | 2,800 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 498 |
| Vaxcyte | 414 |
| Halozyme Therapeutics | 350 |
| Rhythm Pharmaceuticals | 283 |
| Krystal Biotech | 275 |
NUVL News
- 6 days ago - Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - PRNewsWire
- 4 weeks ago - Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones - PRNewsWire
- 7 weeks ago - Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Nuvalent Appoints Ron Squarer to Board of Directors - PRNewsWire
- 2 months ago - Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 2 months ago - Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - PRNewsWire
- 3 months ago - Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - PRNewsWire